Related references
Note: Only part of the references are listed.L-Dopa therapy increases homocysteine concentration in cerebrospinal fluid from patients with Parkinson's disease
Chiaki Isobe et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2010)
Effect of entacapone on plasma homocysteine levels in Parkinson's disease patients
Martin Nevrly et al.
NEUROLOGICAL SCIENCES (2010)
Peripheral COMT inhibition prevents levodopa associated homocysteine increase
Thomas Mueller et al.
JOURNAL OF NEURAL TRANSMISSION (2009)
Homocysteine Is Not Associated with Global Motor or Cognitive Measures in Nondemented Older Parkinson's Disease Patients
Richard M. Camicioli et al.
MOVEMENT DISORDERS (2009)
Homocysteine and Parkinson's disease: A dangerous liaison?
E. Martignoni et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2007)
Plasma homocysteine levels and Parkinson disease: Disease progression, carotid intima-media thickness and neuropsychiatric complications
Sharon Hassin-Baer et al.
CLINICAL NEUROPHARMACOLOGY (2006)
Elevated plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with dyskinesias
Stefano Zoccolella et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2006)
Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: A randomized controlled study
RB Postuma et al.
NEUROLOGY (2006)
The controversy concerning plasma homocysteine in Parkinson disease patients treated with levodopa alone or with entacapone: Effects of vitamin status
Tberesa A. Zesiewicz et al.
CLINICAL NEUROPHARMACOLOGY (2006)
The COMT inhibitor, entacapone, reduces levodopa-induced elevations in plasma homocysteine in healthy adult rats
E Nissinen et al.
JOURNAL OF NEURAL TRANSMISSION (2005)
Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients
P Valkovic et al.
PARKINSONISM & RELATED DISORDERS (2005)
Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications
S Zoccolella et al.
PARKINSONISM & RELATED DISORDERS (2005)
Plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with cognitive dysfunctions
S Zoccolella et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2005)
Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients
P Lamberti et al.
MOVEMENT DISORDERS (2005)
Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease
PE O'Suilleabhain et al.
MOVEMENT DISORDERS (2004)
Elevated plasma homocysteine level in patients with Parkinson disease - Motor, affective, and cognitive associations
PE O'Suilleabhain et al.
ARCHIVES OF NEUROLOGY (2004)
Plasma homocysteine as a risk factor for dementia and Alzheimer's disease.
S Seshadri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Macular microcirculation characteristics in Parkinson's disease evaluated by OCT-Angiography: a literature review
Evita Evangelia Christou et al.
SEMINARS IN OPHTHALMOLOGY
Share Paper
